Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $11.71

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $11.79.

Several research firms have recently weighed in on HCAT. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday. Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Citigroup lifted their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Finally, Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th.

Health Catalyst Price Performance

Shares of HCAT stock opened at $8.65 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock’s fifty day simple moving average is $8.13 and its 200 day simple moving average is $7.30. Health Catalyst has a one year low of $5.42 and a one year high of $11.41. The firm has a market cap of $526.34 million, a price-to-earnings ratio of -6.41 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the firm posted ($0.22) EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts expect that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now owns 134,899 shares in the company, valued at $1,036,024.32. The trade was a 3.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors have recently made changes to their positions in HCAT. Principal Financial Group Inc. boosted its holdings in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after acquiring an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Health Catalyst by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after acquiring an additional 2,164 shares during the last quarter. Creative Planning grew its holdings in Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares during the period. Finally, Quarry LP increased its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.